Abstracts

Pooled Analysis of Randomized Trials Comparing Drug Efficacy for Early COVID-19 During Omicron Waves

Background: Antivirals and monoclonal antibodies are largely used for early treatment of COVID-19 in high-risk people, based on data from randomized trials (RCTs) among unvaccinated people before the omicron era. No evidence from RCTs is available on the comparison of clinical efficacy of currently available treatments. We present a pooled analysis of two RCTs conducted…

A Randomized Trial Switching Adults ≥ 60 Years Old From First-Line ART to B/F/TAF: Week 48 Results

Background: Age-related comorbidities and toxicities of some antiretrovirals (ART) limit treatment options for the aging population of people living with HIV. We evaluated the efficacy and safety of switching older adults from a first-line regimen to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF). Methods: The B/F/TAF-elderly study is an open-label, randomized, active controlled, non-inferiority trial conducted at two sites…

A Randomized, Adaptive Phase I Study to Determine the Phase II Dose of VIR-7832: AGILE CST5

Background: Despite widespread COVID-19 vaccination, anti-virals remain important for COVID-19 treatment. Early treatment is crucial to avoid progression and severe disease, with monoclonal antibodies (mAb) offering possible advantages in single dosing and duration of effect. VIR-7832 is a novel mAb derived from the same parental antibody as sotrovimab with addition of an Fc domain XX2…

Factors Affecting TFV-DP Concentrations in PBMC and Relationships With DBS in PWH on TAF-Based ART

Background: Relationships between tenofovir-diphosphate (TFV-DP) steady-state concentrations (Css) in peripheral blood mononuclear cells (PBMCs), dried blood spots (DBS), and adherence have not been well-described in people with HIV (PWH) on tenofovir-alafenamide (TAF)-containing antiretroviral therapy (ART). Our objectives were to assess the influence of adherence and other factors on TFV-DP Css in PBMCs, and to examine…

Focal Cerebral Hypoperfusion in Individuals With Cognitive Impairment After COVID-19

Background: Cognitive impairment is a common symptom of neuropsychiatric post-acute sequelae of COVID-19 (N-PASC), characterized by neuropsychological deficits including impaired executive functioning, processing speed, motor speed, attention, recall, and verbal fluency. Little is known about the underlying mechanism of cognitive N-PASC. We report preliminary analyses of noninvasive MRI measurements of brain perfusion in individuals with…

Impact of Recombination on HIV-1 Evolutionary Dynamics in CSF and Plasma

Background: HIV-1 is capable of establishing distinct viral populations within CNS, leading to a spectrum of neuronal complications. An improved understanding of HIV-1 evolutionary dynamics across the CNS and plasma is necessary to inform vaccine and cure efforts and longitudinal assessments are lacking. Methods: We used single genome amplification to generate full-length HIV-1 env (>2.5Kb)…

No Neurocognitive Benefit of Tesamorelin Immediate vs Delayed Treatment in Virally-Suppressed PWH

Background: In people with HIV (PWH) who are virally suppressed (VS) on antiretroviral therapy (ART), abdominal obesity (AO) is associated with neurocognitive impairment (NCI). The likely mechanisms involve visceral adiposity, inflammation, and reductions in insulin-like growth factor type 1 (IGF-1), a neurotrophin. Tesamorelin (Tesa) is a synthetic growth hormone-releasing hormone that reduces AO and increases…